Clinical Trials - December 23, 2014
BenGenBio Drug Moves Forward
Norway’s BerGenBio has finished up a $15 million round to push its lead Axl kinase inhibitor into new Phase I and Phase II studies for acute myeloid leukemia. BerGenBio is in the early stages of developing a pipeline of epithelial-mesenchymal transition (EMT) inhibitors, with three antibodies and a small molecule for triple negative breast cancer in the […]